Companies / Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

Nasdaq: GRCECIK 1444192PRINCETON, NJ

Financials · FY2023

Revenue$100.00M
Net income$-7.79M
Total debt—
Cash$13.76M
Diluted EPS$-0.47
Shares outstanding21.0M

Ownership

21.0M shares outstanding · as of Aug 11, 2026
13.1%10%+ / strategic
Ownership
10%+ / strategic13.07%2,748,392
Institutions21.81%4,587,271
Public float65.13%13,700,267

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Davis a BrianFormerDirector
——
Kavuru VimalFormerDirector
——
Kottayil GeorgeFormerDirector
——
Neugeboren EdwardFormerDirector
——

Institutional holders 25

View all →
HolderValue% of shares
Nantahala Capital Management, LLC$4.08M5.60%
AIGH Capital Management LLC$3.15M4.31%
ADAR1 Capital Management, LLC$2.22M3.05%
Bank of America Corp /De$1.71M2.35%
Vanguard Group Inc$1.48M2.02%
Cerity Partners LLC$1.46M2.01%
Renaissance Technologies LLC$1.13M1.16%
Marshall Wace, LLP$423.3K0.43%
Citadel Advisors LLC$147.6K0.20%
XTX Topco Ltd$105.6K0.14%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 8, 2026Kavuru Vimal
Director
GrantStock Option (Right to Buy)—+10K
10,000
0.05% of shares
low
Jan 8, 2026Kottayil George
Director
GrantStock Option (Right to Buy)—+10K
10,000
0.05% of shares
low
Jan 8, 2026Neugeboren Edward
Director
GrantStock Option (Right to Buy)—+10K
10,000
0.05% of shares
low
Jan 8, 2026Davis a Brian
Director
GrantStock Option (Right to Buy)—+10K
10,000
0.05% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Opaleye Management Inc.Passive13G—2,748,392—
Orin HirschmanPassive13G/A———
Nantahala Capital Management, LLCPassive13G/A———
ADAR1 Capital Management, LLCPassive13G/A———
Orin HirschmanPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
GRCE——00439U104—